As price pressure intensifies in crowded therapy areas, healthcare systems are increasingly reliant on the introduction of generics and biosimilars in order to reduce spending. In this research, we test if physicians’ price sensitivity is sufficient to drive cost reductions alone, or if payer-led controls and guidelines must be implemented to effect this change.
Overcoming the funding challenges of bringing digital health technologies to market
Digital health is a rapidly emerging field showing significant potential to improve the quality and efficiency of healthcare systems around the world, and more...